However, clinical trials in Rett patients treated with saritozan, a 5HT1aR- and D2R-agonist, were unsuccessful (Evaluation of the Efficacy, Safety, and Tolerability of Sarizotan in Rett Syndrome with Respiratory Symptoms (STARS), 2021). The gene discussed is DRD2; the disease is Rett syndrome.